NO310287B1 - <alfa>-substituerte pyrimidintioalkyl- og alkyleterforbindelser og farmasöytisk preparat inneholdende dissesom inhibitorer av viral reverstranskriptase - Google Patents

<alfa>-substituerte pyrimidintioalkyl- og alkyleterforbindelser og farmasöytisk preparat inneholdende dissesom inhibitorer av viral reverstranskriptase Download PDF

Info

Publication number
NO310287B1
NO310287B1 NO19975129A NO975129A NO310287B1 NO 310287 B1 NO310287 B1 NO 310287B1 NO 19975129 A NO19975129 A NO 19975129A NO 975129 A NO975129 A NO 975129A NO 310287 B1 NO310287 B1 NO 310287B1
Authority
NO
Norway
Prior art keywords
chloro
amino
compound
mmol
thiopyrimidine
Prior art date
Application number
NO19975129A
Other languages
English (en)
Norwegian (no)
Other versions
NO975129L (no
NO975129D0 (no
Inventor
Richard Allen Nugent
Donn G Wishka
Gary J Cleek
David R Graber
Stephen Thomas Schlachter
Martin J Murphy
Joel Morris
Richard Charles Thomas
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO975129D0 publication Critical patent/NO975129D0/no
Publication of NO975129L publication Critical patent/NO975129L/no
Publication of NO310287B1 publication Critical patent/NO310287B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO19975129A 1995-05-08 1997-11-07 <alfa>-substituerte pyrimidintioalkyl- og alkyleterforbindelser og farmasöytisk preparat inneholdende dissesom inhibitorer av viral reverstranskriptase NO310287B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43670895A 1995-05-08 1995-05-08
PCT/US1996/006119 WO1996035678A1 (en) 1995-05-08 1996-05-03 Alpha-substituted pyrimidine-thioalkyl and alkylether compounds as inhibitors of viral reverse transcriptase

Publications (3)

Publication Number Publication Date
NO975129D0 NO975129D0 (no) 1997-11-07
NO975129L NO975129L (no) 1998-01-07
NO310287B1 true NO310287B1 (no) 2001-06-18

Family

ID=23733510

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975129A NO310287B1 (no) 1995-05-08 1997-11-07 <alfa>-substituerte pyrimidintioalkyl- og alkyleterforbindelser og farmasöytisk preparat inneholdende dissesom inhibitorer av viral reverstranskriptase

Country Status (27)

Country Link
US (1) US6043248A (ru)
EP (2) EP0824524B1 (ru)
JP (1) JPH11507017A (ru)
KR (1) KR100445498B1 (ru)
CN (2) CN1535958A (ru)
AT (1) ATE275550T1 (ru)
AU (1) AU712404B2 (ru)
BR (1) BR9608265A (ru)
CA (1) CA2216099C (ru)
CZ (1) CZ293135B6 (ru)
DE (1) DE69633332T2 (ru)
ES (1) ES2227586T3 (ru)
GE (1) GEP20002297B (ru)
HK (1) HK1009446A1 (ru)
HU (1) HUP9801995A3 (ru)
IL (1) IL118075A0 (ru)
MX (1) MX9708582A (ru)
NO (1) NO310287B1 (ru)
NZ (1) NZ307089A (ru)
PL (1) PL323240A1 (ru)
PT (1) PT824524E (ru)
RU (1) RU2167155C2 (ru)
SK (1) SK150297A3 (ru)
TW (1) TW450962B (ru)
UA (1) UA56992C2 (ru)
WO (1) WO1996035678A1 (ru)
ZA (1) ZA963281B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124306A (en) * 1997-09-25 2000-09-26 Pharmacia & Upjohn Company Thioalkyl alpha substituted pyrimidine compounds
US6111111A (en) * 1997-10-23 2000-08-29 Kuraray Co., Ltd. Intermediates for producing pyridine derivatives
WO2000015229A1 (en) 1998-09-17 2000-03-23 Bristol-Myers Squibb Company METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
CA2376951A1 (en) 1999-06-30 2001-01-04 Peter J. Sinclair Src kinase inhibitor compounds
JP2003523942A (ja) 1999-06-30 2003-08-12 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
JP2003503351A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害化合物
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
US7923056B2 (en) 2007-06-01 2011-04-12 Illinois Tool Works Inc. Method and apparatus for dispensing material on a substrate
CA2762680C (en) 2009-05-21 2018-04-17 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
CN101638391B (zh) * 2009-08-21 2011-04-27 山东大学 2-[(取代苯氨基)羰基甲硫基]-6-(2,6-二氯苄基)-3h-嘧啶-4-酮类衍生物及其制备方法与应用
US9226970B2 (en) 2010-02-22 2016-01-05 Nektar Therapeutics Oligomer modified diaromatic substituted compounds
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
BR112013000043A2 (pt) * 2010-07-02 2019-09-24 Gilead Sciences Inc derivados de ácido naft-2-ilacético para tratar aids
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
KR101360587B1 (ko) * 2012-11-01 2014-03-10 현대자동차주식회사 스마트 도어 언록 시스템
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
GB201807898D0 (en) * 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
EP4093198A4 (en) * 2020-01-20 2024-01-24 Agrematch Ltd. COMPOSITIONS FOR CROP PROTECTION
CN114057707A (zh) * 2021-11-24 2022-02-18 上海应用技术大学 一种n-4-吲哚基-2-呋喃甲酰胺化合物的制备方法
CN118715205A (zh) * 2022-01-12 2024-09-27 艾福姆德尤股份有限公司 用于治疗与sting活性相关的病症的化合物和组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2295560A (en) * 1941-06-18 1942-09-15 Gen Electric Pyrimidine derivatives
GB744867A (en) * 1952-10-29 1956-02-15 American Cyanamid Co Improvements relating to 2-substituted-mercapto-4-amino-6-disubstituted-aminopyrimidines and acid addition salts thereof
US3940394A (en) * 1972-03-31 1976-02-24 Santilli Arthur A 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides
ATE25255T1 (de) * 1983-05-05 1987-02-15 Heumann Ludwig & Co Gmbh Pyrimidin-thioalkylpyridin-derivate, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel.
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
JPS62209062A (ja) * 1986-03-10 1987-09-14 Yamanouchi Pharmaceut Co Ltd ２−ピリジルメチルチオ−または２−ピリジルメチルスルフイニル−置換縮合環化合物
JPH07107056B2 (ja) * 1987-01-30 1995-11-15 日清製粉株式会社 ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤
AU3752589A (en) * 1988-05-16 1989-12-12 Georgia State University Research Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
HU203736B (en) * 1989-04-06 1991-09-30 Gyogyszerkutato Intezet Process for producing new thiouracil-derivatives and pharmaceutical compositions containing them
AU654808B2 (en) * 1989-12-28 1994-11-24 Pharmacia & Upjohn Company Diaromatic substituted anti-aids compounds
US5668136A (en) * 1990-09-25 1997-09-16 Eisai Co., Ltd. Trisubstituted benzene derivatives, composition and methods of treatment
DE69217224T2 (de) * 1991-07-03 1997-06-05 Pharmacia & Upjohn Co., Kalamazoo, Mich. Substituierte indole als anti-aids pharmaceutische zubereitungen
GB2266716A (en) * 1992-05-05 1993-11-10 Merck & Co Inc Inhibitors of HIV reverse transcriptase
JP3077046B2 (ja) * 1992-08-31 2000-08-14 久光製薬株式会社 新規なキナゾリン誘導体
JPH09502713A (ja) * 1993-09-17 1997-03-18 ジ・アップジョン・カンパニー Ｈｉｖおよび他のレトロウイルス病を治療するのに有用な置換テトロン酸
JPH09505050A (ja) * 1993-11-12 1997-05-20 ジ・アップジョン・カンパニー ピリミジン−チオアルキルおよびアルキルエーテル化合物
WO1995029897A1 (en) * 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
KR970704688A (ko) * 1994-07-20 1997-09-06 헤르베르트 루프; 울리히 볼프 헬리코박터 박테리아 제거용 티오피리딜 화합물(thiopyridyl compounds for controlling helicobacter bacteria)

Also Published As

Publication number Publication date
BR9608265A (pt) 1999-02-02
IL118075A0 (en) 1996-08-04
TW450962B (en) 2001-08-21
EP1449835A2 (en) 2004-08-25
US6043248A (en) 2000-03-28
CN1535958A (zh) 2004-10-13
HUP9801995A3 (en) 1999-04-28
GEP20002297B (en) 2000-11-25
WO1996035678A1 (en) 1996-11-14
UA56992C2 (ru) 2003-06-16
EP0824524A1 (en) 1998-02-25
NO975129L (no) 1998-01-07
MX9708582A (es) 1998-02-28
AU712404B2 (en) 1999-11-04
NZ307089A (en) 1999-07-29
CA2216099A1 (en) 1996-11-14
KR100445498B1 (ko) 2004-11-16
SK150297A3 (en) 1998-10-07
ATE275550T1 (de) 2004-09-15
RU2167155C2 (ru) 2001-05-20
HUP9801995A2 (hu) 1999-03-29
HK1009446A1 (en) 1999-09-10
EP0824524B1 (en) 2004-09-08
CN1183773A (zh) 1998-06-03
CZ293135B6 (cs) 2004-02-18
CA2216099C (en) 2005-09-13
DE69633332T2 (de) 2005-09-22
PL323240A1 (en) 1998-03-16
ZA963281B (en) 1997-10-24
KR19990008400A (ko) 1999-01-25
DE69633332D1 (de) 2004-10-14
AU5635396A (en) 1996-11-29
ES2227586T3 (es) 2005-04-01
CN1152022C (zh) 2004-06-02
PT824524E (pt) 2005-01-31
CZ349197A3 (cs) 1998-04-15
JPH11507017A (ja) 1999-06-22
NO975129D0 (no) 1997-11-07
EP1449835A3 (en) 2004-09-15

Similar Documents

Publication Publication Date Title
NO310287B1 (no) &lt;alfa&gt;-substituerte pyrimidintioalkyl- og alkyleterforbindelser og farmasöytisk preparat inneholdende dissesom inhibitorer av viral reverstranskriptase
DE69624010T2 (de) Sulfonamide Derivate und Verfahren zu deren Herstellung
TWI475996B (zh) 雜芳基化合物及其用途
DE69724789T2 (de) Bicyclische heteroaromatic verbindungen als protein tyrosin kinase inhibitoren
US5981537A (en) Pyrimidine-thioalkyl and alkylether compounds
EA010380B1 (ru) Лиганды ванилоидных рецепторов
JP2006508997A (ja) Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
NO321120B1 (no) Forbindelser nyttige som anti-inflammatoriske midler, og anvendelse derav, samt farmasoytisk sammensetning.
NO314182B1 (no) Nikotinamid-derivater, anvendelse derav, samt farmasöytisk blanding
WO2006099974A1 (en) N-aryl-sulfoximine-substituted pyrimidines as cdk- and/or vegf inhibitors, their production and use as pharmaceutical agents
CA2667447A1 (en) Mapk/erk kinase inhibitors
AU2009208712B2 (en) Novel heterocycles
CN110437253A (zh) 含联苯结构的二芳基嘧啶并环化合物及其制备方法和用途
AU2016366443A1 (en) Aminoazole derivative
JPH0899961A (ja) ベンゼンスルホンアミド誘導体及びその製法
TW200305567A (en) Compounds and use thereof for decreasing activity of hormonesensitive lipase